Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Hepion completes first cohort enrollment in Phase 2 trial of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) enrolled the last patient in the 75 mg cohort of its Phase 2 ‘AMBITION’ clinical trial evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “We are pleased to...

November 10, 2020

Developments

Monopar Therapeutics gets new patents for Validive

Monopar Therapeutics (NASDAQ:MNPR) received additional patents for its Phase 2b/3 clinical-stage candidate, Validive. Monopar is developing Validive for the prevention of chemoradiation-induced severe oral mucositis in...

November 9, 2020

Developments

Corbus Pharma updates Phase 3 systemic sclerosis study results

Corbus Pharmaceuticals (NASDAQ:CRBP) updated data from its Phase 3 study of lenabasum for the treatment of systemic sclerosis. Systemic sclerosis is an autoimmune disease characterized by inflammation and fibrosis...

November 9, 2020

Developments

Entera Bio completes enrollment in Phase 2 osteoporosis trial

Entera Bio (NASDAQ:ENTX) completed enrollment in its Phase 2 trial evaluating EB613 for the treatment of osteoporosis. EB613 is an orally delivered human parathyroid hormone designed to build bone in osteoporosis...

November 9, 2020

Developments

IntelGenx reports montelukast effect on neurological aging published in peer-reviewed journal

IntelGenx (TSXV:IGX; OTCQB:IGXT) reported that the peer-reviewed International Journal of Clinical Pharmacy published a study on montelukast’s effect on aging. IntelGenx is currently conducting a Phase...

November 9, 2020

Developments

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen (NASDAQ:HGEN) reported positive interim results from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients. Lenzilumab is an antibody that targets granulocyte-macrophage colony-stimulating...

November 6, 2020

Developments

LogicBio gets FDA fast track designation for methylmalonic acidemia

LogicBio Therapeutics’ (NASDAQ:LOGC) LB-001 received FDA fast track designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in genes responsible for the breakdown of certain proteins...

November 4, 2020

Developments

Cassava Sciences reports additional data from Phase 2b Alzheimer’s disease trial

Cassava Sciences (NASDAQ:SAVA) reported additional data from its Phase 2b study of sumifilam for the treatment of Alzheimer’s disease (AD). The study enrolled 64 patients with mild-to-moderate AD, 50-to-85 years of age...

November 4, 2020

Developments

Concert Pharmaceuticals launches Phase 3 alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) initiated a Phase 3 trial to evaluate CTP-543 for the treatment of alopecia areata. Alopecia areata is an autoimmune disease that causes partial or complete loss of hair on the...

November 3, 2020

Developments

Titan Pharma completes debt settlement with Molteni and Horizon; acquisition of JT-09

Titan Pharmaceuticals (NASDAQ:TTNP) settled all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio and Horizon Credit, as well as the acquisition of JT Pharmaceuticals’ JT-09. Completion...

November 2, 2020

Developments

Zucara Expands ZT-01 Development to Type 2 Diabetes

Closely-held Zucara Therapeutics is expanding the development of ZT-01, which is currently in a Phase 1 trial for the prevention of insulin-induced hypoglycemia in patients with Type 1 Diabetes...

November 2, 2020

Developments

Cerevel doses first patients in three Phase 3 Parkinson’s disease trials

Cerevel Therapeutics (NASDAQ:CERE) dosed the first patients in each of its three Phase 3 trials evaluating tavapadon for the treatment of Parkinson’s disease (PD). Tavapadon is an oral, once-daily partial agonist...

October 30, 2020

Developments

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

Humanigen (NASDAQ:HGEN) reported that the National Institutes of Health (NIH) has dosed the first hospitalized COVID-19 patient with lenzilumab. Lenzilumab is an antibody that targets granulocyte-macrophage colony...

October 29, 2020

Developments

BioLineRx initiates Phase 2 first-line metastatic pancreatic cancer trial

BioLineRx (NASDAQ:BLRX) launched a Phase 2 trial evaluating motixafortide, in combination with cemiplimab and standard-of-care chemotherapy, in first-line metastatic pancreatic ductal adenocarcinoma (PDAC)...

October 29, 2020

Developments

MediWound completes enrollment in Phase 3 pediatric burn study

MediWound (NASDAQ:MDWD) completed enrollment in a Phase 3 study evaluating NexoBrid for the treatment of burns in patients 18 years of age and younger. NexoBrid is a topically administered biological product that...

October 29, 2020

Developments

IntelGenx inks binding LOI with Heritage for cannabis filmstrip supply

IntelGenx (TSXV:IGX; OTCQB:IGXT) signed a binding letter of intent (LOI) with Heritage Cannabis (CSE:CANN; OTCQX:HERTF) for the supply of CBD-containing filmstrip products for the Canadian and Australian markets. Under...

October 29, 2020

Developments

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to acquire JT Pharmaceuticals’ kappa opioid agonist peptide, JT-09, for use in combination with Titan’s ProNeura long-term, continuous drug delivery technology, for...

October 28, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Prevail Therapeutics’ (NASDAQ:PRVL) PR001 received FDA fast track designation for the treatment of neuronopathic Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the...

October 27, 2020

Developments

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Taysha Gene Therapies (NASDAQ:TSHA) received FDA rare pediatric and orphan drug designations for TSHA-104 for the treatment of SURF1-associated Leigh syndrome. Leigh syndrome is a severe neurological disorder that...

October 27, 2020

Developments

Imagin Medical reports agenda for KOL virtual investor event on Oct. 29

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) reported the agenda for its KOL virtual investor event taking place on Oct. 29 at 12:00 pm ET. Presenters include Jim Hutchens, Imagin’s...

October 26, 2020

Developments

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Hepion Pharmaceuticals (NASDAQ:HEPA) will present virtually at the Roth Capital “therapeutic approaches for COVID-19” event taking place on Oct. 28 from 9:00 am to 1:20 pm ET; and at the B. Riley Securities...

October 26, 2020

Developments

Titan Pharma in debt settlement pact with Molteni and Horizon

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio and Horizon Credit. The debt was secured with a lien on all assets...

October 26, 2020

Subscribe